ABVC logo

ABVC BioPharma (ABVC) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 November 2004

Indexes:

Not included

Description:

ABVC BioPharma is a biotechnology company focused on developing innovative therapies for various diseases. They specialize in creating treatments for cancer and other serious health conditions, using advanced technology and research to improve patient outcomes and enhance quality of life.

Key Details

Price

$0.53

Annual Revenue

$152.40 K(-84.29% YoY)

Annual EPS

-$2.43(+53.18% YoY)

Annual ROE

-185.02%

Beta

0.48

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

July 25, 2023

Analyst ratings

Recent major analysts updates

16 Nov '22 Maxim Group
Hold

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
ABVC
globenewswire.com22 October 2024

FREMONT, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has received a total of $346,000 in licensing fees from its strategic partners, supporting our partner's belief in our mission. ABVC has received 23M AiBtl shares as part of the first milestone of the licensing fees and will obtain royalties up to $100M after the product launches.

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
ABVC
globenewswire.com15 August 2024

• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) --   ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1.

Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
ABVC
PennyStocks26 October 2023

If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.

FAQ

  • What is the primary business of ABVC BioPharma?
  • What is the ticker symbol for ABVC BioPharma?
  • Does ABVC BioPharma pay dividends?
  • What sector is ABVC BioPharma in?
  • What industry is ABVC BioPharma in?
  • What country is ABVC BioPharma based in?
  • When did ABVC BioPharma go public?
  • Is ABVC BioPharma in the S&P 500?
  • Is ABVC BioPharma in the NASDAQ 100?
  • Is ABVC BioPharma in the Dow Jones?
  • When was ABVC BioPharma's last earnings report?
  • When does ABVC BioPharma report earnings?
  • Should I buy ABVC BioPharma stock now?

What is the primary business of ABVC BioPharma?

ABVC BioPharma is a biotechnology company focused on developing innovative therapies for various diseases. They specialize in creating treatments for cancer and other serious health conditions, using advanced technology and research to improve patient outcomes and enhance quality of life.

What is the ticker symbol for ABVC BioPharma?

The ticker symbol for ABVC BioPharma is NASDAQ:ABVC

Does ABVC BioPharma pay dividends?

No, ABVC BioPharma does not pay dividends

What sector is ABVC BioPharma in?

ABVC BioPharma is in the Healthcare sector

What industry is ABVC BioPharma in?

ABVC BioPharma is in the Biotechnology industry

What country is ABVC BioPharma based in?

ABVC BioPharma is headquartered in United States

When did ABVC BioPharma go public?

ABVC BioPharma's initial public offering (IPO) was on 10 November 2004

Is ABVC BioPharma in the S&P 500?

No, ABVC BioPharma is not included in the S&P 500 index

Is ABVC BioPharma in the NASDAQ 100?

No, ABVC BioPharma is not included in the NASDAQ 100 index

Is ABVC BioPharma in the Dow Jones?

No, ABVC BioPharma is not included in the Dow Jones index

When was ABVC BioPharma's last earnings report?

ABVC BioPharma's most recent earnings report was on 14 November 2024

When does ABVC BioPharma report earnings?

The next expected earnings date for ABVC BioPharma is 14 March 2025

Should I buy ABVC BioPharma stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions